Glycoengineering Can Reframe Therapeutic Protein Function Without Changing Its Primary Sequence

Therapeutic proteins are commonly interpreted through primary sequence, higher-order structure, and dose, yet glycosylation can change function while leaving the encoded amino-acid sequence intact. This perspective argues that glycan state should be treated as a configurable functional layer whose meaning is conditional on biosynthetic context, molecular topology, receptor mechanism, product heterogeneity, and manufacturing history. Evidence from therapeutic antibodies, Fc-containing proteins, and other glycoprotein platforms shows that glycan composition, positional isomerism, pairing, and terminal processing can alter Fc-receptor engagement, complement activity, circulatory persistence, and immune-cell handling. The same literature also exposes an important limit: analytically detectable glycan differences do not automatically propagate into clinically meaningful differences, and engineering success cannot be inferred from a desired glycan shift alone. Cellular engineering, process manipulation, model-based control, and predictive proxies can modify or estimate glycan quality within defined domains, but transfer across products, scales, sites, and clinical contexts requires separate validation. We therefore develop a mechanistic perspective in which glycoengineering is interpreted as controlled movement through linked biosynthetic, product-quality, molecular-interaction, biological-response, and translational boundaries. The central claim is not that one glycoform is universally superior, but that primary-sequence-identical proteins can occupy functionally different states whose relevance depends on where and how the glycan difference propagates.